Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Designing Special RBCs for the delivery of Therapeutic Proteins

Flavored E-cigarettes cause lung cell toxicity

Light Up the Dark: Bioluminescence in Organisms

Designing Special RBCs for the delivery of Therapeutic Proteins
  • BiotechToday
  • World

Designing Special RBCs for the delivery of Therapeutic Proteins

bioxone December 19, 2020December 19, 2020

Anannya Roy, Amity University Kolkata

Protein replacement therapy is a medical treatment that supplements or replaces a protein in a patient in whom this is absent or deficient. These are a very powerful class of drugs and are highly selective and specific in their targets. This makes them a very useful tool in modern science. However, just like nothing in the world is perfect, this therapy as well has certain limitations. Proteins are easily degraded by the enzymes present in our body or filtered from the blood by kidneys. 

Recently researchers at ACS Central Science have engineered a special type of RBC (red blood cell) carriers with the help of a honey bee peptide that when stimulated by light could release therapeutic proteins. This strategy is not only limited to RBC carriers but is also applicable to nano transporters and micro transporters composed of the lipid bilayer membrane. 

Because of the above-stated reasons, protein drugs are unstable in the body. To produce desired outcomes they are given in high amounts, which cause side effects. Degradation has been prevented by enclosing the proteins within carriers like liposomes, nanoparticles and RBCs, but the biggest challenge has been how to release the products in proper place and time.

In the paper, Brianna Vickerman, David Lawrence and their colleagues engineered a special kind of RBCs that would release proteins at certain regions of the body, only when triggered by a particular wavelength of light. 

Melittin is a component of European honey bee venom. The researchers embedded this peptide into the membrane of the red blood cells (RBC). Under normal circumstances, this Melittin would degrade the cells but here they were modified in such a way that they’ll do so only when illuminated by the light of a certain wavelength. Thrombin, a blood-clotting enzyme that stops bleeding was inserted into these special RBCs and injected into mice ears. A small portion was illuminated and upon examination, it was found that blood clotting occurred only in the illuminated sections. 

This research provides a lot of insights into how Protein therapy can be modified in ways that it would be useful to a wide range of the population.

Also read:Flavored E-cigarettes cause lung cell toxicity

Citation- https://pubs.acs.org/doi/abs/10.1021/acscentsci.0c01151

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged allergies bioanalysis bioengineering Biomolecules Biotechnology blood clotting cell membrane drugs enzymes Gene honey bees Kidneys lipids liposomes Medicine Melittin mice nanotransporters peptide Population proteins RBCs reactions red blood cells thrombin venom

2 thoughts on “Designing Special RBCs for the delivery of Therapeutic Proteins”

  1. Pingback: Light Up the Dark: Bioluminescence in Organisms - BioXone
  2. Pingback: Human Gene in Fruit Fly Helps in MGS Study - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Biotechnopedia
  • DNA-Tales

Light Up the Dark: Bioluminescence in Organisms

bioxone December 20, 2020

Priasha Dutta, Amity University Kolkata Bioluminescence can be undoubtedly regarded as one of the most stunningly beautiful and captivating abilities that Mother Nature has bestowed to some of its beings on this planet. This rather unique property is possessed and depicted by a comparatively small population of organisms on the planet. It is the phenomenon […]

Bioluminescence

Related Post

  • BiotechToday
  • India

SIGN TO START PHASE 1 HUMAN TRIAL OF “ANTISERA”-DCGI

bioxone October 7, 2020October 7, 2020

Aishila Kar, Amity University Kolkata ICMR officials said on Tuesday that The Drugs Controller General of India has given authorization for conducting Phase-1 human clinical trial for an “antisera” that was developed by injecting inactivated SARS-CoV-2 in horses and can be a treatment for COVID-19. The Indian Council of Medical Research (ICMR) in alliance with a Hyderabad-based vaccine maker […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

A skunk-like creature, who were the companions of Dinosaurs found!

bioxone April 19, 2021April 19, 2021

Ayooshi Mitra, Amity University Kolkata In Chilean Patagonia, a fossil sample of a skunk-like animal from the dinosaur time has been identified, adding to current evidence that mammals roamed that part of South America much earlier than previously thought. Close to the famous Torres del Paine national park, a portion of the creature’s fossilized jawbone […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

USEFULNESS OF CGX-1321 IN OVARIAN CANCER TREATMENT

bioxone November 17, 2020November 16, 2020

Biswadeep Sen, Amity University Kolkata Ovarian Cancer is one of the most notorious forms of cancers, causing pain and discomfort to 1 in 108 women worldwide. Immune checkpoint therapy has shown that the presence of Immune Phenotypes limits its efficacy against this deadly foe. The previous digging had shed light upon the Wnt/β-catenin pathway and […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy